a public good project by the
Synthesis
Company
of California

© 2026

Simonetta Buglioni | doi.page

0 works0 citations0 h-index

Simonetta Buglioni

National Cancer Institute(MY)Istituti di Ricovero e Cura a Carattere Scientifico(IT)

Publications by Year

Research Areas

Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies

Most-Cited Works

→ The α3β1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (mmp-9) activity(2000)265 cited
→ c-Myb and Bcl-x Overexpression Predicts Poor Prognosis in Colorectal Cancer(2001)133 cited
→ PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer(2021)117 cited
→ BCL-XL overexpression promotes tumor progression-associated properties(2017)112 cited
→ A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study(2008)107 cited
→ Prognostic relevance of altered Fas (CD95)-system in human breast cancer(2000)103 cited

→ HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care(2011)

98 cited

→ Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: Independent prognostic role of p53 and bcl-2(1999)98 cited

→ High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors(2014)91 cited

→ Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma(2019)85 cited